Llwytho...
Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody–drug conjugate), blinatumomab (a bispecific T-cell engager), and chimeric anti...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Drugs Context |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioExcel Publishing Ltd
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7560100/ https://ncbi.nlm.nih.gov/pubmed/33110433 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.2020-7-2 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|